Plasminogen activator for the treatment of acute inflammatory and chronic interstitial lung diseases
Production of a recombinant chimeric fusion protein, consisting of human plasminogen activator (urokinase or u-PA) and human hydrophobic surfactant protein (SP-B, SP-C).<br>
Persistent suppression of alveolar fibrinolytic activity and the resulting permanent intra-alveolar fibrin deposition play an important pathomechanistic role in acute inflammatory and chronic interstitial lung diseases. In this process, the polymerization of fibrinogen to fibrin in the presence of lung surfactant causes incorporation of the surfactant into the growing fibrin matrix, which is associated with loss of surface activity, an altered fibrin structure, and enhanced resistance of fibrin to fibrinolytic proteases. In addition, the blocking of u-PA dependent processes is also linked with reduced activation of hepatocyte growth factor (HGF), which protects the epithelium.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Bringing bio-inspired robots to life
Nebraska researcher Eric Markvicka gets NSF CAREER Award to pursue manufacture of novel materials for soft robotics and stretchable electronics. Engineers are increasingly eager to develop robots that mimic the…
Bella moths use poison to attract mates
Scientists are closer to finding out how. Pyrrolizidine alkaloids are as bitter and toxic as they are hard to pronounce. They’re produced by several different types of plants and are…
AI tool creates ‘synthetic’ images of cells
…for enhanced microscopy analysis. Observing individual cells through microscopes can reveal a range of important cell biological phenomena that frequently play a role in human diseases, but the process of…
